Literature DB >> 8350616

Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia.

W H Raskind1, A M Ferraris, V Najfeld, R J Jacobson, J W Moohr, P J Fialkow.   

Abstract

The Ph chromosome abnormality is involved in the pathogenesis of almost all patients with chronic myelocytic leukemia (CML). Previous studies on the B-lymphoid cell lineage in two patients with Ph-positive CML suggest that there may also be a clonal Ph-negative stage in CML and that the Ph-positive stage arises by subclonal expansion. To determine whether this is a frequent or a rare occurrence, 14 additional glucose-6-phosphate dehydrogenase (G6PD)-heterozygous patients with CML were studied. In five of these patients there was a statistically significant excess of Ph-negative B-lymphoid cell lines expressing the same G6PD type expressed in the corresponding CML clone. In no case was an excess of B-lymphoid lines expressing the opposite G6PD type recovered. These data provide further evidence that in some patients the Ph chromosome arises in a pluripotent stem cell from a pre-existing Ph-negative clone that enjoys a growth advantage.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8350616

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell.

Authors:  R Tominaga; T Katagiri; K Kataoka; K Kataoka; R K C Wee; A Maeda; H Gomyo; I Mizuno; T Murayama; S Ogawa; S Nakao
Journal:  Leukemia       Date:  2015-10-06       Impact factor: 11.528

2.  Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.

Authors:  Sureyya Bozkurt; Burak Uz; Yahya Buyukasik; Ozlen Bektas; Ayten Inanc; Hakan Goker; Emin Kansu
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

3.  Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.

Authors:  T Era; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

4.  Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.

Authors:  M Schmidt; J Rinke; V Schäfer; S Schnittger; A Kohlmann; E Obstfelder; C Kunert; J Ziermann; N Winkelmann; E Eigendorff; T Haferlach; C Haferlach; A Hochhaus; T Ernst
Journal:  Leukemia       Date:  2014-09-12       Impact factor: 11.528

5.  Megakaryocytes carry the fused bcr-abl gene in chronic myeloid leukaemia: a fluorescence in situ hybridization analysis from bone marrow biopsies.

Authors:  M Nolte; M Werner; M Ewig; R von Wasielewski; H Link; H Diedrich; A Georgii
Journal:  Virchows Arch       Date:  1996-03       Impact factor: 4.064

6.  ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.

Authors:  Lioba Schönfeld; Jenny Rinke; Anna Hinze; Saskia N Nagel; Vivien Schäfer; Thomas Schenk; Christian Fabisch; Tim H Brümmendorf; Andreas Burchert; Philipp le Coutre; Stefan W Krause; Susanne Saussele; Fatemeh Safizadeh; Markus Pfirrmann; Andreas Hochhaus; Thomas Ernst
Journal:  Leukemia       Date:  2022-07-28       Impact factor: 12.883

Review 7.  Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.

Authors:  Simona Soverini; Manuela Mancini; Luana Bavaro; Michele Cavo; Giovanni Martinelli
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.